Namenda and Application site irritation - a phase IV clinical study of FDA data

Summary:

Application site irritation is reported as a side effect among people who take Namenda (memantine hydrochloride), especially for people who are male, 60+ old, also take Exelon, and have Dementia alzheimer's type.

The phase IV clinical study analyzes which people have Application site irritation when taking Namenda. It is created by eHealthMe based on reports of 13,521 people who have side effects when taking Namenda from the FDA, and is updated regularly.

What is Namenda?

Namenda has active ingredients of memantine hydrochloride. It is often used in dementia. eHealthMe is studying from 14,283 Namenda users. Check the latest studies of Namenda.

What is Application site irritation?

Application site irritation is found to be associated with 392 drugs and 698 conditions by eHealthMe. Check the latest studies of Application site irritation.

On Jul, 14, 2026

13,521 people reported to have side effects when taking Namenda.
Among them, 15 people (0.11%) have Application site irritation.

Could Namenda cause Application site irritation?

Among these 15 people:

What is the gender of people who have Application site irritation when taking Namenda? *

female: 46.67 %
male: 53.33 %

What is the age of people who have Application site irritation when taking Namenda? *

What are other drugs people take besides Namenda? *

What are other side effects people have besides Application site irritation? *

Application Site Erythema (redness of the skin at application site): 10 people, 66.67%
Application Site Pruritus (application site severe itching of the skin): 8 people, 53.33%
Application Site Dermatitis: 4 people, 26.67%
High Blood Pressure: 4 people, 26.67%
Rashes (redness): 3 people, 20.00%
Abdominal Discomfort: 2 people, 13.33%
Salivary Hypersecretion (excess saliva secretion): 2 people, 13.33%
Fatigue (feeling of tiredness): 2 people, 13.33%
Headache (pain in head): 2 people, 13.33%
Drug Ineffective: 2 people, 13.33%

What are the existing conditions these people have? *

Dementia Alzheimer's Type (loss of mental ability with alzheimer's symptom): 5 people, 33.33%
High Blood Cholesterol: 2 people, 13.33%
Urinary Incontinence (inability to control the flow of urine and involuntary urination): 1 person, 6.67%
Urge Incontinence (urinary incontinence): 1 person, 6.67%
Sleep Disorder: 1 person, 6.67%
Neuropathy Peripheral (surface nerve damage): 1 person, 6.67%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 6.67%
Bone Disorder: 1 person, 6.67%
Bladder Disorder: 1 person, 6.67%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Namenda and have Application site irritation?

- Check whether Application site irritation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Namenda:

Namenda (14,283 reports)

Browse all side effects of Namenda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Application site irritation:

Application site irritation (392 drugs)

Browse all the conditions that are associated with Application site irritation:

Application site irritation (698 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on memantine hydrochloride (the active ingredients of Namenda) and Namenda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.